|
Up a level |
Steiner, U; Marconato, Maddalena (2017). Patienten unter Therapie mit Immunglobulinen. Der informierte @rzt:34-35.
Adamo, S; Nilsson, J; Krebs, A; Steiner, U; Cozzio, A; French, L E; Kolios, A G A (2017). Successful treatment of SAPHO syndrome with apremilast. British Journal of Dermatology:Epub ahead of print.
Marschall, K; Hoernes, M; Bitzenhofer-Grüber, M; Jandus, P; Duppenthaler, A; Wuillemin, W A; Rischewski, J; Boyman, O; Heininger, U; Hauser, T; Steiner, U; Posfay-Barbe, K; Seebach, J; Recher, M; Hess, C; Helbling, A; Reichenbach, J (2015). The Swiss National Registry for Primary Immunodeficiencies: report on the first 6 years' activity from 2008 to 2014. Clinical and Experimental Immunology, 182(1):45-50.
Recher, M; Sahrbacher, U; Bremer, J; Arndt, B; Steiner, U; Fontana, A (2012). Treatment of inclusion body myositis: is low-dose intravenous immunoglobulin the solution? Rheumatology International, 32(2):469-472.
Müller, U R; Jutel, M; Reimers, A; Zumkehr, J; Huber, C; Kriegel, C; Steiner, U; Haeberli, G; Akdis, M; Helbling, A; Schnyder, B; Blaser, K; Akdis, C A (2008). Clinical and immunologic effects of H1 antihistamine preventive medication during honeybee venom immunotherapy. Journal of Allergy and Clinical Immunology, 122(5):1001-1007.